Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 2941 AL 2955

Involvement of GABAergic interneuron dysfunction and neuronal network hyperexcitability in Alzheimer's disease: Amelioration by metabolic switching

Mattson MP.

Int Rev Neurobiol. 2020;154:191-205. doi: 10.1016/bs.irn.2020.01.006. Epub 2020 Jul 10.

Status and future directions of clinical trials in Alzheimer's disease

Plascencia-Villa G, Perry G.

Int Rev Neurobiol. 2020;154:3-50. doi: 10.1016/bs.irn.2020.03.022. Epub 2020 Jul 20.

A social dancing pilot intervention for older adults at high risk for Alzheimer's disease and related dementias

Blumen HM, Ayers E, Wang C, Ambrose AF, Verghese J.

Neurodegener Dis Manag. 2020 Aug;10(4):183-194. doi: 10.2217/nmt-2020-0002. Epub 2020 Aug 3.

Mesenchymal Stem Cell Therapy and Alzheimer's Disease: Current Status and Future Perspectives

Kim J, Lee Y, Lee S, Kim K, Song M, Lee J.

J Alzheimers Dis. 2020;77(1):1-14. doi: 10.3233/JAD-200219.

Anti-amyloid-β protein agents for the treatment of Alzheimer's disease: an update on emerging drugs

Lozupone M, Solfrizzi V, D'Urso F, Di Gioia I, Sardone R, Dibello V, Stallone R, Liguori A, Ciritella C, Daniele A, Bellomo A, Seripa D, Panza F.

Expert Opin Emerg Drugs. 2020 Sep;25(3):319-335. doi: 10.1080/14728214.2020.1808621. Epub 2020 Aug 20.

Potential cost savings for selected non-pharmacological treatment strategies for patients with Alzheimer's disease in Finland

Rosenvall A, Sääksvuori L, Finne-Soveri H, Linnosmaa I, Malmivaara A.

J Rehabil Med. 2020 Sep 30;52(9):jrm00106. doi: 10.2340/16501977-2722.

A multitude of signaling pathways associated with Alzheimer's disease and their roles in AD pathogenesis and therapy

Gadhave K, Kumar D, Uversky VN, Giri R.

Med Res Rev. 2021 Sep;41(5):2689-2745. doi: 10.1002/med.21719. Epub 2020 Aug 11.

Design and Validation of Liposomal ApoE2 Gene Delivery System to Evade Blood-Brain Barrier for Effective Treatment of Alzheimer's Disease

Arora S, Layek B, Singh J.

Mol Pharm. 2021 Feb 1;18(2):714-725. doi: 10.1021/acs.molpharmaceut.0c00461. Epub 2020 Sep 16.

Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval

Tolar M, Abushakra S, Hey JA, Porsteinsson A, Sabbagh M.

Alzheimers Res Ther. 2020 Aug 12;12(1):95. doi: 10.1186/s13195-020-00663-w.

Immunological Features of Non-neuronal Brain Cells: Implications for Alzheimer's Disease Immunotherapy

Castellani G, Schwartz M.

Trends Immunol. 2020 Sep;41(9):794-804. doi: 10.1016/j.it.2020.07.005. Epub 2020 Aug 13.

NLRP3 Inflammasome: A Potential Therapeutic Target in Fine Particulate Matter-Induced Neuroinflammation in Alzheimer's Disease

Shi JQ, Wang BR, Jiang T, Gao L, Zhang YD, Xu J.

J Alzheimers Dis. 2020;77(3):923-934. doi: 10.3233/JAD-200359.

Fiat Lux: The Light Became Therapy. An Overview on the Bright Light Therapy in Alzheimer's Disease Sleep Disorders

Roccaro I, Smirni D.

J Alzheimers Dis. 2020;77(1):113-125. doi: 10.3233/JAD-200478.

Expanded access: opening doors to personalized medicine for rare disease patients and patients with neurodegenerative diseases

Özdinler PH.

FEBS J. 2021 Mar;288(5):1457-1461. doi: 10.1111/febs.15529. Epub 2020 Sep 5.

Alzheimer's Disease and Specialized Pro-Resolving Lipid Mediators: Do MaR1, RvD1, and NPD1 Show Promise for Prevention and Treatment?

Miyazawa K, Fukunaga H, Tatewaki Y, Takano Y, Yamamoto S, Mutoh T, Taki Y.

Int J Mol Sci. 2020 Aug 12;21(16):5783. doi: 10.3390/ijms21165783.

The potential role of nanoyttria in alleviating oxidative stress biomarkers: Implications for Alzheimer's disease therapy

Tang KS.

Life Sci. 2020 Oct 15;259:118287. doi: 10.1016/j.lfs.2020.118287. Epub 2020 Aug 16.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias